1996
Search results
Sandoz is a global leader in generic pharmaceuticals and biosimilars, with a mission to discover new ways to improve and extend people's lives. Learn more about our products, our quality standards, our innovation and sustainability efforts, and our partnerships and collaborations.
Sandoz | 924,531 followers on LinkedIn. Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally.
The company was founded in 1886 by Alfred Kern (1850–1893) and Edouard Sandoz (1853–1928) in Basel (Switzerland) under the name Chemiefirma Kern und Sandoz. Initially the company focused on production of dyes namely alizarin blue and auramine .
<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PVQMF29>m_auth=>m_preview=>m_cookies_win=x" height="0" width="0" style="display:none;visibility ...
Oct 4, 2023 · Novartis today completed the Spin-off of Sandoz, its Generics and Biosimilars business, through a dividend-in-kind distribution to holders of Novartis shares and American Depositary Receipts (ADRs), with each holder receiving one Sandoz share for every five Novartis shares or one Sandoz ADR for every five Novartis ADRs, held at the close of ...
Pioneering access for patients | Sandoz is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to discover new ways to improve and extend people's lives.
Oct 4, 2023 · Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-off; Shares of Sandoz will be listed and commence trading today on the SIX Swiss Exchange; Spin-off allows shareholders to benefit from a Novartis with capital and management attention fully focused on innovative medicines
IgAN nephropathy (IgAN) is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide. Novartis is working to slow the progression of this disease and extend a dialysis-free life in patients. Learn more.
Sandoz US is a part of a global leader in generic and biosimilar medicines, with a mission to pioneer access for patients and improve their lives.
This report provides a comprehensive overview of Sandoz, including our business, strategy, governance and performance.
